CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has described pyrimidine and nitrogen-containing 6-membered aromatic heterocyclic compounds acting as S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.